/PRNewswire/ The "Global Single Cell RNA Sequencing Market - A Global and Regional Analysis: Focus on Product, Workflow, End User and Application, Supply.
/PRNewswire/ The "Global Single Cell RNA Sequencing Market - A Global and Regional Analysis: Focus on Product, Workflow, End User and Application, Supply.
/PRNewswire/ The "Transcriptomics Market - Global and Regional Analysis 2021-2031" report has been added to ResearchAndMarkets.com s offering. The growth of.
Spatial Genomics and Transcriptomics Market, 2030
News provided by
Share this article
Share this article
ResearchAndMarkets.com s offering.
Global Spatial Genomics and Transcriptomics Market to Reach $2,173.0 Million by 2030, progressing at a CAGR of 23.20%.
The market is driven by certain factors, which include the increasing prevalence of various types of genetic disorders, such as cancer, neurological disorder, and rare diseases, inciting the development of high-resolution multiplex assays and instruments, technological advancements in sequencing technologies, and significant research funding in the field of spatial-based technology for executing R&D exercises.
The market is favored by the development of spatial profiling-based solutions for visualization and analysis of tissue microenvironment, tumor biology, and tissue biomarker. The gradual increase in the prevalence of neurological disorders and rare diseases globally has furthered the spatial genomics and transcripto
How and when to submit research applications to ARSAC
Guide to submitting research applications to the Administration of Radioactive Substances Advisory Committee (ARSAC).
From: Contents
ARSAC) research approval for all your research projects where the protocol:
requires the administration of radioactive substances
specifies the frequency, activity or processing for an administration that would otherwise be considered standard care
You do not need to obtain
ARSAC research approval for research projects where:
the protocol does not specify any administrations of radioactive substances
the only administration of a radioactive substance mentioned in the protocol is an inclusion criterion that would be received by all participants as part of standard care, for example, a trial where all participants must have received a radioiodine therapy to be considered eligible